Eye Detection to Identify Novel Coronavirus Infection
Risk Screening Based on Feature Recognition and Detection of Eye Surface Images of COVID-2019 Patients and Statistical Analysis of High-dimensional Data
1 other identifier
observational
232
1 country
1
Brief Summary
The eye characteristics of patients with COVID-19 and those without the disease were analyzed, and whether they had the disease or not was judged according to the eye characteristics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 22, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 26, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 26, 2021
CompletedFirst Submitted
Initial submission to the registry
May 23, 2021
CompletedFirst Posted
Study publicly available on registry
June 1, 2021
CompletedJune 14, 2021
June 1, 2021
3 months
May 23, 2021
June 11, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Collection and analysis of eye characteristics of patients encoding criteria, annotation of ocular feature
Ocular pathological features
1DAY
Study Arms (3)
Novel coronavirus infection
All patients were diagnosed according to the diagnostic criteria of the National Health Commission of China and confirmed by RT-PCR detection of viral nucleic acids.
Not infected by novel coronavirus
Healthy controls and patients with liver disease
Recovered patients with nucleic acid negative after infection with novel coronavirus
Novel coronavirus nucleic acid changed from positive to negative.
Interventions
Using eye examination to judge whether novel coronavirus is infected or not.
Eligibility Criteria
Hospital
You may qualify if:
- All participants were provided with written informed consent at the time of recruitment；
- Age ≥ 18 and ≤ 75 (informed consent signed by guardian under 18)
- Meet the diagnostic criteria of novel coronavirus (2019-COVID-19) infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, 050024, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lei zhao
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- OTHER
- Target Duration
- 1 Day
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 23, 2021
First Posted
June 1, 2021
Study Start
January 22, 2021
Primary Completion
April 26, 2021
Study Completion
April 26, 2021
Last Updated
June 14, 2021
Record last verified: 2021-06